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Objectives: The purpose of this study was to verify the feasibility of using the
glyceraldehyde-3-phosphate dehydrogenase (GAP) promotor based Pichia pas-
toris expression system to produce tick-borne encephalitis virus (TBEV) virus-like
particles (VLPs).
Methods: The complementary DNA encoding the TBEV prM signal peptide, prM,
and E proteins of TBEV Korean strain (KrM 93) was cloned into the plasmid vector
pGAPZɑA, then integrated into the genome of P. pastoris, under the control of
the GAP promoter. Expression of TBEV VLPs was determined by Western blotting
using monoclonal antibody against TBEV envelope (E) protein.
Results: Recombinant TBEV VLPs consisting of prM and E protein were success-
fully expressed using the GAP promoter-based P. pastoris expression system. The
results of Western blotting showed that the recombinant proteins were secreted
into the culture supernatant from the P. pastoris and glycosylated.
Conclusion: This study suggests that recombinant TBEV VLPs from P. pastoris
offer a promising approach to the production of VLPs for use as vaccines and
diagnostic antigens.1. Introduction
Tick-borne encephalitis virus (TBEV) belongs to the
Flavivirus genus of the Flaviviridae family and can
cause fatal encephalitis in humans in Europe, Russia,
and Far East Asia [1,2]. In South Korea, TBEV was first
isolated from wild rodents in 2006 [3]. The flavivirus
genome contains a single, long, open reading frame thatted under the terms of the
) which permits unrestrict
operly cited.
ase Control and Preventionencodes a polyprotein, which is cleaved into three
structural proteins, i.e., the capsid (C), premembrane
(prM) and envelope (E) proteins, and seven nonstruc-
tural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) [4]. In flaviviruses, the prM and E
proteins play crucial roles in the assembly and secretion
of the virions [5e8]. Several studies have demonstrated
that flavivirus virus-like particles (VLPs), consisting ofCreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
Recombinant tick-borne encephalitis 275the prM and E proteins, have been shown to be similar
to the native virions in the structural and functional
features for infection [5,9e12]. Thus, flavivirus VLPs
can be substituted for native virions in investigations
into the biological features of flavivirus, such as vaccine
study for the prevention of flavivirus-induced diseases.
Until recently, various expression systems, including
mammalian cells and insect cells, have been used to
produce TBEV VLPs as antigens [10,13,14].
Pichia pastoris is one of the most widely used systems
for producing recombinant protein by heterologous
expression [15]. This system offers several advantages in
comparison with other eukaryotic expression systems,
such as the production of large-scale target proteins in their
native conformation and cost-efficiency, and the proven
safety of yeast-expressed VLPs vaccines such as hepatitis
B virus VLPs [16] and human papillomavirus VLPs [17].
For this reason, the P. pastoris expression system has been
used for the production of flavivirus proteins including
VLPs [18e21]. However, there are no reports on the
production of TBEV VLPs from P. pastoris. In the current
study, we investigated the expression of TBEV VLPs
using the glyceraldehyde-3-phosphate dehydrogenase
(GAP) promoter-based P. pastoris expression system.
To our knowledge, this is the first report on the
successful expression of TBEV VLPs in P. pastoris.2. Materials and methods
2.1. Viruses and cells
The TBEV Korean isolate, KrM 93 strain (GenBank
accession No. HM535611), was propagated in the brains
of suckling mice and BHK-21 cell as described previ-
ously [22]. The infected cell culture medium was used
for RNA extraction.
2.2. Yeast strain and plasmid vector
The P. pastoris host strain X33 (Invitrogen, Carlsbad,
CA, USA) was used as the expression host in this study.
The expression vector pGAPZɑA (Invitrogen) contains the
selectable marker Zeocin (Invitrogen), which is bifunc-
tional in both P. pastoris and Escherichia coli, the GAP
promoter, and the alcohol oxidase I (AOX1) transcription
termination regions.E. coli transformants were selected on
low salt Luria-Bertani agar plates containing 25 mg/mL
Zeocin. P. pastoris transformants were selected on YPDS
plates (1% yeast extract, 2% peptone, 2% dextrose, 1M
sorbitol, 2% agar, and 100 mg/mL Zeocin) and P. pastoris
liquid cell cultures were grown in YPD broth (1% yeast
extract, 2% peptone, and 2% dextrose) with Zeocin.
2.3. Construction of recombinant expression
vector
The coding sequence for the signal peptide of prM,
prM, and E proteins was amplified from KrM 93 strain
viral RNA by reverse transcription-polymerase chainreaction (RT-PCR) using SuperScript III First-strand
synthesis system for RT-PCR (Invitrogen) and Ex Taq
DNA polymerase (Takara, Shiga, Japan) according to
the manufacturer’s instructions, and the following
primers: KrM93SS-F 50-GAC TTC GAA ATG GTT
GGC TTG CAA AAA-30 (Bst BI site in bold and start
codon in italics) and KrM93E-R 50-GAA TCT AGA
GCT GCC CCC ACT CCA AGG-30 (Xba I site in bold).
The PCR product (named as 93prM-E) was first cloned
into pCR 2.1-TOPO plasmid (Invitrogen) and then
subcloned into pGAPZɑA following enzymatic diges-
tion using Bst BI and Xba I (New England BioLabs
Inc., Beverley, MA, USA) to construct the full-length
93prM-E clone downstream of GAP promoter, which
was designated as pGAPZɑA/93prM-E (Figure 1A). The
plasmid inserts were confirmed by DNA sequencing.
2.4. Yeast transformation
The plasmid pGAPZɑA/93prM-E was linearized
with Bgl II (New England BioLabs) and transformed
into P. pastoris X33 using Pichia EasyComp Kit
(Invitrogen) according to the manufacturer’s in-
structions. The transformed yeast cells were incubated
in YPDS agar containing 100 mg/mL Zeocin at 30e for
3e4 days. Zeocin-resistant yeast colonies were selected
and identification of the insert in these Zeocin-resistant
transformants was checked by colony PCR.
2.5. Expression of recombinant TBEV E protein
in P. pastoris
Positive transformants, selected as described previ-
ously, were inoculated in 5 mL YPD broth with 100 mg/
mL Zeocin with shaking (250 rpm) at 30C overnight.
These cultures were transferred to 500 mL of YPD broth
with Zeocin with shaking (250 rpm) at 30C for 48
hours. The culture supernatant and cell pellet were
collected by centrifugation at 10,000  g for 10 minutes.
The cell pellet was disrupted using Yeast PE LB (G-
Biosciences, St. Louis, MO, USA) according to the
manufacturer’s instructions. The lysate was clarified by
centrifugation at 20,000  g for 30 minutes at 4C. The
culture supernatant was precipitated by using Amicon
Ultra-15 Centrifugal Filter Units with 30 kDa membrane
(Millipore, Billerica, MA, USA) according to the man-
ufacturer’s instructions.
2.6. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blot analysis
The protein samples were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) on a reduced 4e12% Bis-Tris Gel (Invi-
trogen). Separated protein bands were transferred onto a
0.45-mm polyvinylidene difluoride membrane using the
iBlot system (Invitrogen) according to the manufac-
turer’s instructions. The membrane was blocked with
5% skim milk in Tris buffered saline with 0.05%
Figure 1. Construction of recombinant plasmid pGAPZɑA/93prM-E. (A) Scheme for cloning the 93prM-E fragment into the
pGAPZɑA vector. (B) Confirmation of vector and insert by digestion with the restriction enzymes, Bst BI and Xba I. bp Z base
pairs, E Z envelope protein; Lane M Z 1 Kb DNA plus ladder; Lane 1 Z pGAPZɑA/93prM-E digested with Bst BI and Xba I;
prM Z premembrane protein; S Z the signal peptide of prM.
276 S.-M. Yun, et alTween-20. TBEV E protein was detected using mono-
clonal anti-TBEV E antibody (8A7 mAb, in-house) as
the primary antibody and horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin G (Prom-
ega, Madison, WI, USA) as the secondary antibody. The
bands were visualized by enhanced chemiluminescence
(GenDEPOT, Barker, TX, USA).
2.7. Analysis of glycosylation patterns of
recombinant TBEV E protein
Glycosylation patterns of recombinant E protein in
lysate and supernatant were analyzed by digestion using
N-glycosidase F (PNGase F) and endoglycosidase H
(Endo H; New England BioLabs) according to the
manufacturer’s instructions. Glycosidase-treated protein
samples were analyzed by SDS-PAGE and Western
blotting as described previously.3. Results
3.1. Construction of recombinant plasmid
containing TBEV prM and E genes
The full-length prM and E genes of TBEV KrM 93
strain about 2 kb in size were amplified by using the RT-
PCR method previously described. The 93prM-E frag-
ment was then inserted into the yeast expression vector
pGAPZɑA to construct a recombinant plasmid
pGAPZɑA/93prM-E. The insert was confirmed by
digestion with the restriction enzymes, Bst BI and Xba I
(Figure 1B).
3.2. Expression of recombinant TBEV VLPS in
P. pastoris
The pGAPZɑA/93prM-E plasmid was transformed
into P. pastoris and positive clones were selected. Yeast
Figure 2. Western blot analysis on the expression of tick-
borne encephalitis virus E protein in Pichia pastoris. Lane
1 Z plasmid alone control; Lane 2 Z sample from the cell
lysate; Lane 3 Z sample from the culture supernatant.
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analyzed for expression of E proteins by Western blot-
ting using TBEV mAb 8A7. As shown in Figure 2, the
specific recombinant E protein bands with a molecular
mass of w55 kDa were detected in both the lysate and
supernatant, but not in the plasmid-alone control. This
result demonstrated that the recombinant TBEV VLPs
were secreted into the culture supernatant from the yeast
cell.
The glycosylation state of E protein in TBEV VLPs
were examined with Endo H, which is specific for high
mannose-type oligosaccharides and PNGase F, which
cleaves both high mannose- and complex-type oligo-
saccharides. Comparison of glycosidase-treated recom-
binant TBEV E protein from yeast cell lysate and
culture supernatant by SDS-PAGE and Western blotting
indicated that the recombinant E protein was glycosy-
lated in the P. pastoris expression system (Figure 3).
4. Discussion
VLPs have been developed as effective vaccine
candidates, because they mimic the organization and
conformation of native virion without containing the
viral full genome, and thus are a safe and highly
immunogenic antigen. Among the various protein
expression systems for VLPs production, the yeast
expression system as an alternative eukaryotic expres-
sion system is a well-established platform for the effi-
cient production of heterologous viral glycoproteins.
Previous studies have reported that this system has been
used for the generation of flaviviral glycoproteins
[18e21]. Among the yeast expression systems, the
protein expression level in the P. pastoris expressionFigure 3. Analysis of glycosylation of tick-borne encephalitis v
pGAPZɑA/93prM-E. Samples from (A) the cell lysate and (B) the c
and compared with untreated controls () by sodium dodecyl sul
Z E protein; Z deglycosylated E protein; Endo H Z esystem was reportedly higher than that in another yeast
Saccharomyces cerevisiae [23] and the GAP promoter
based P. pastoris expression system can improve the
protein yield compared to the P. pastoris by using
methanol-inducible AOXI promoter [24]. We therefore
have selected the P. pastoris expression system under
the control of the GAP promoter to produce the TBEV
VLPs in this study.
Here, we demonstrated the efficient production of
TBEV VLPs, consisting of the prM and E proteins by
using the GAP promoter-based P. pastoris expression
system. The KrM 93 strain, which belongs to the
Western subtype of TBEV isolated in South Korea [22],
was used for production of recombinant proteins. As a
main structural protein of flavivirus, the E protein plays
important roles in receptor binding, membrane fusion
activity, and immunogenicity [25,26]. The prM gene
was included in the recombinant plasmid pGAPZɑA/
93prM-E because E protein requires coexpression of the
prM protein to maintain its native conformation and the
protection of E protein from conformational alteration
during transportation through the acidic compartments
of the trans-Golgi network [27e29].
The results of Western blotting indicated that the
TBEV VLPs were secreted into the culture supernatant
from P. pastoris, suggesting that the signal peptide of
prM can induce the secretion of TBEV VLPs, and
coexpression of prM and E proteins in yeast cells may
play an important role in virus particle release as shown
in previous studies [5e9]. In addition, analysis of
glycosylation of TBEV E protein in P. pastoris trans-
formed with plasmid pGAPZɑA/93prM-E showed that
the recombinant E protein from P. pastoris was glyco-
sylated by eukaryotic posttranslational modifications
(Figure 3).
This is the first study to report the successful cloning
and expression of TBEV VLPs by using the GAP
promoter-based P. pastoris expression system, and this
study demonstrated that recombinant TBEV VLPs from
P. pastoris offer a promising approach to the production
of VLPs for use as vaccines and diagnostic antigens.
Further study will be required for the purification of
TBEV VLPs from P. pastoris and to identify the
immunogenicity in a mouse model.irus E proteins in Pichia pastoris transformed with plasmid
ell supernatant were treated with Endo H (þ) or PNGase F (þ)
fate-polyacrylamide gel electrophoresis and Western blotting.
ndoglycosidase H; PNGase Z N-glycosidase F.
278 S.-M. Yun, et alConflicts of interest
The authors declare no conflicts of interest.
Acknowledgments
This research was funded by an intramural grant from
the Korea National Institute of Health (grant number.
2013-NG53001-00).
References
1. Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin Infect
Dis 1999 Apr;28(4):882e90.
2. Ecker M, Allison SL, Meixner T, et al. Sequence analysis and
genetic classification of tick-borne encephalitis viruses from
Europe and Asia. J Gen Virol 1999 Jan;80(Pt 1):179e85.
3. Kim SY, Yun SM, Han MG, et al. Isolation of tick-borne
encephalitis viruses from wild rodents, South Korea. Vector
Borne Zoonotic Dis 2008 Spring;8(1):7e13.
4. Chambers TJ, Hahn CS, Galler R, et al. Flavivirus genome orga-
nization, expression, and replication. Annu Rev Microbiol 1990;
44:649e88.
5. Allison SL, Stadler K, Mandl CW, et al. Synthesis and secretion of
recombinant tick-borne encephalitis virus protein E in soluble and
particulate form. J Virol 1995 Sep;69(9):5816e20.
6. Kim JM, Yun SI, Song BH, et al. A single N-linked glycosylation
site in the Japanese encephalitis virus prM protein is critical for
cell type-specific prM protein biogenesis, virus particle release,
and pathogenicity in mice. J Virol 2008 Aug;82(16):7846e62.
7. Mackenzie JM, Westaway EG. Assembly and maturation of the
flavivirus Kunjin virus appear to occur in the rough endoplasmic
reticulum and along the secretory pathway, respectively. J Virol
2001 Nov;75(22):10787e99.
8. Goto A, Yoshii K, Obara M, et al. Role of the N-linked glycans of
the prM and E envelope proteins in tick-borne encephalitis virus
particle secretion. Vaccine 2005 Apr 27;23(23):3043e52.
9. Wu CJ, Li TL, Huang HW, et al. Development of an effective
Japanese encephalitis virus-specific DNA vaccine. Microbes Infect
2006 Sep;8(11):2578e86.
10. Schalich J, Allison SL, Stiasny K, et al. Recombinant subviral
particles from tick-borne encephalitis virus are fusogenic and
provide a model system for studying flavivirus envelope glyco-
protein functions. J Virol 1996 Jul;70(7):4549e57.
11. Zhang S, Liang M, Gu W, et al. Vaccination with dengue virus-
like particles induces humoral and cellular immune responses in
mice. Virol J 2011;8:333.
12. Wang PG, Kudelko M, Lo J, et al. Efficient assembly and secre-
tion of recombinant subviral particles of the four dengue serotypes
using native prM and E proteins. PLoS One 2009;4(12):e8325.
13. Yoshii K, Hayasaka D, Goto A, et al. Enzyme-linked immuno-
sorbent assay using recombinant antigens expressed in mammaliancells for serodiagnosis of tick-borne encephalitis. J Virol Methods
2003 Mar;108(2):171e9.
14. Liu YL, Si BY, Hu Y, et al. [Expression of tick-borne encephalitis
virus prM-E protein in insect cells and studies on its antigenicity].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2005 Dec;
19(4):335e9 [Article in Chinese].
15. Macauley-Patrick S, Fazenda ML, McNeil B, et al. Heterologous
protein production using the Pichia pastoris expression system.
Yeast 2005 Mar;22(4):249e70.
16. Leroux-Roels G, Desombere I, De Tollenaere G, et al. Hepatitis B
vaccine containing surface antigen and selected preS1 and preS2
sequences. 1. Safety and immunogenicity in young, healthy adults.
Vaccine 1997 Nov;15(16):1724e31.
17. Bryan JT. Developing an HPV vaccine to prevent cervical cancer
and genital warts. Vaccine 2007 Apr 20;25(16):3001e6.
18. Tang YX, Jiang LF, Zhou JM, et al. Induction of virus-neutralizing
antibodies and T cell responses by dengue virus type 1 virus-like
particles prepared from Pichia pastoris. Chin Med J (Engl) 2012
Jun;125(11):1986e92.
19. Kwon WT, Lee WS, Park PJ, et al. Protective immunity of Pichia
pastoris-expressed recombinant envelope protein of Japanese en-
cephalitis virus. J Microbiol Biotechnol 2012 Nov;22(11):1580e7.
20. Liu W, Jiang H, Zhou J, et al. Recombinant dengue virus-like
particles from Pichia pastoris: efficient production and immuno-
logical properties. Virus Genes 2010 Feb;40(1):53e9.
21. Sugrue RJ, Fu J, Howe J, et al. Expression of the dengue virus
structural proteins in Pichia pastoris leads to the generation of
virus-like particles. J Gen Virol 1997 Aug;78(Pt 8):1861e6.
22. Yun SM, Kim SY, Ju YR, et al. First complete genomic charac-
terization of two tick-borne encephalitis virus isolates obtained
from wild rodents in South Korea. Virus Genes 2011 Jun;42(3):
307e16.
23. Cereghino JL, Cregg JM. Heterologous protein expression in the
methylotrophic yeast Pichia pastoris. FEMS Microbiol Rev 2000
Jan;24(1):45e66.
24. Vassileva A, Chugh DA, Swaminathan S, et al. Expression of
hepatitis B surface antigen in the methylotrophic yeast Pichia
pastoris using the GAP promoter. J Biotechnol 2001 Jun 1;88(1):
21e35.
25. McMinn PC. The molecular basis of virulence of the encephali-
togenic flaviviruses. J Gen Virol 1997 Nov;78(Pt 11):2711e22.
26. Gritsun TS, Holmes EC, Gould EA. Analysis of flavivirus enve-
lope proteins reveals variable domains that reflect their antige-
nicity and may determine their pathogenesis. Virus Res 1995 Mar;
35(3):307e21.
27. Konishi E, Mason PW. Proper maturation of the Japanese en-
cephalitis virus envelope glycoprotein requires cosynthesis with
the premembrane protein. J Virol 1993 Mar;67(3):1672e5.
28. Heinz FX, Stiasny K, Puschner-Auer G, et al. Structural changes
and functional control of the tick-borne encephalitis virus glyco-
protein E by the heterodimeric association with protein prM.
Virology 1994 Jan;198(1):109e17.
29. Zhang Y, Corver J, Chipman PR, et al. Structures of immature
flavivirus particles. EMBO J 2003 Jun 2;22(11):2604e13.
